ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer
Status:
Recruiting
Trial end date:
2026-03-05
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test how well patients with advanced solid tumors and ovarian
cancer respond to treatment with BAY1895344 in combination with niraparib. In addition
researchers want to find for patients the optimal dose of BAY1895344 in combination with
niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges
the drug. The study medication BAY1895344 works by blocking a substance produced by the body
(ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a
substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or
made more susceptible to chemotherapy.